2160.T
Latest Trade
1,696.00JPYChange
-33.00(-1.91%)Volume
557,200Today's Range
-
1,742.0052 Week Range
-
2,731.00As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 1,729.00 |
|---|---|
Open | 1,739.00 |
Volume | 557,200 |
3M AVG Volume | 23.67 |
Today's High | 1,742.00 |
Today's Low | 1,695.00 |
52 Week High | 2,731.00 |
52 Week Low | 835.33 |
Shares Out (MIL) | 43.40 |
Market Cap (MIL) | 73,615.64 |
Forward P/E | -- |
Dividend (Yield %) | -- |
GNI Group unit receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product
GNI Group gets IND clearance by FDA for liver fibrosis treatment
GNI Group unit says clearance of IND by FDA for F351 clinical trials in the treatment of liver fibrosis
GNI Group Ltd. is a Japan-based company engaged in new drug production activities utilizing biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. It is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
Contact Info
3F, Nihonbashi-Honcho YS Bldg
2-2-2, Nihonbashi Hon-cho
+81.3.62143600
http://www.gnipharma.com/Executive Leadership
Ying Luo
President, Representative Executive Officer, Chief Executive Officer, Chairman and CEO of Subsidiaries, Director
Thomas Eastling
Chief Financial Officer, Representative Executive Officer, Director
Takashi Kataoka
Director
Sadayuki Yasukawa
Director
Wanshou Guo
Independent Director
Price To Earnings (TTM) | 184.72 |
|---|---|
Price To Sales (TTM) | 9.89 |
Price To Book (MRQ) | 6.76 |
Price To Cash Flow (TTM) | 68.52 |
Total Debt To Equity (MRQ) | 18.73 |
LT Debt To Equity (MRQ) | 10.63 |
Return on Investment (TTM) | 5.87 |
Return on Equity (TTM) | 4.44 |
* Says unit Berkeley Advanced Biomaterials receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product in U.S. from FDA
* GNI Group announces clearance of investigational new drug (IND) by FDA for F351 clinical trials in the treatment of liver fibrosis
* Says its wholly-owned subsidiary GNI USA, Inc had received U.S. FDA clearance on Sept. 29 (U.S. local time) for the Investigational New Drug application (IND) for F351 for U.S. clinical trials in the treatment of liver fibrosis
* Says 4,082 units of its 40th series options were exercised to 4.1 million shares of its common stock, from July 3 to July 18
* Says its wholly owned unit GNI USA, Inc will sell 242,029 voting rights in IriSys, LLC to EPS Americas, Corp., for $3.8 million (425.2 million yen), on July 31, and will cut voting power in IriSys, LLC to 15 percent from 35 percent
* Says 2,102 units of its 40th series options were exercised to 2,102,000 shares of its common stock from June 15 to June 20
* Says 5,909 units of its 40th series options were exercised to 5.9 million shares of its common stock, from June 13 to June 14
* Says 2,196 units of its 40th series options were exercised to 2.2 million shares of its common stock from June 5 to June 12
* Says 2,055 units of its 40th series options were exercised to 2.1 million shares of its common stock on June 1 and June 2
* Says 2,536 of its 40th series options were exercised to 2.5 million shares, during period from May 9 to May 25
* Says it will acquire 70 percent voting power of a new unit of Berkeley Advanced Biomaterials, Inc., for $59.7 million (6.51 billion yen), through GNI USA, Inc.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.